Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/NEU testing

Breast Cancer Research and Treatment

Volumn 74, Issue 2, 2002, Pages 113-120

  Gancberg, David ^a   Järvinen, Tero ^b   Di Leo, Angelo ^a   Rouas, Ghizlane ^a   Cardoso, Fatima ^a   Paesmans, Marianne ^a   Verhest, Alain ^a   Piccart, Martine J ^a   Isola, Jorma ^b   Larsimont, Denis ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antigen retrieval; Breast cancer; HER 2 neu; Immunohistochemistry; Reproducibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; ONCOPROTEIN; UNCLASSIFIED DRUG;

ANTIGEN RETRIEVAL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LABORATORY TEST; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM; STANDARDIZATION; TECHNIQUE; TUMOR BIOPSY; BIOSYNTHESIS; BREAST TUMOR; GENETICS; LABORATORY; OBSERVER VARIATION; PATHOLOGY; STANDARD;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; OBSERVER VARIATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0035990725     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016146130767     Document Type: Article

References (43)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer
3. Molecular mechanisms underlying ErbB2/HER 2 action in breast cancer
4. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
5. Prognostic importance of c-erbB- 2 expression in breast cancer
6. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
7. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
8. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
9. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
10. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
11. Effects of HER-2/neu on chemosensitivity of tumour cells
12. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment
13. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER- 2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
14. Combination therapy with tratuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
16. Overview of the trastuzumab (Herceptin) anti-HER-2 monoclonal antibody clinical program in HER-2-overexpressing metastatic breast cancer
17. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer
18. Assessment of HER-2 status in breast cancer: Why, when and how?
19. ERBB 2 amplification in breast cancer analyzed by fluorescence in situ hybridization
20. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
21. HER-2/neu amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
22. Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
23. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
24. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use
25. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
26. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
27. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
28. Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison in immunohistochemistry assay with fluorescence in situ hybridization assays
29. Sastre-Garau X Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of ERBB2 (HER-2/neu) gene status in breast carcinoma
30. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
31. Specificity of HercepTest in determinig HER-2/neu status of breast cancers using the US FDA-approved scoring system
32. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
33. C-erbB-2 immunostaining: Problems with interpretation
34. CMF or anthracycline-based adjuvant chemotherapy for node-positive breast cancer patients: 4 year results of a Belgian randomised clinical trial with predictive markers analysis
35. Predictive value of topo-isomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
36. Genetic alterations in ErbB- 2 amplified breast carcinomas
37. Amplification and deletion of topoisomerase IIa gene are common in ErbB- 2 amplified breast cancer and alter the sensitivity to doxorubicin
38. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases
39. Increased HER-2 with U.S. Food and Drug Administration-approved antibody
40. Effects of antigen retrieval by microwave heating in formalin-fixed tissue sections on a broad panel of antibodies
41. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
42. The concordance between the clinical trial assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials